ECOR1 CAPITAL, LLC

other names
{{ Info.Overview }}
Revenue {{ Info.Revenue | formatUSD }}
Headquarters {{ Info.Headquarters }}
cb

Adviser Profile
As of Date 03/28/2024
Adviser Type - Large advisory firm
Number of Employees 21 23.53%
of those in investment advisory functions 8 14.29%
Registration SEC, Approved, 7/2/2015
Other registrations (2)
AUM* 5,001,741,440 6.15%
of that, discretionary 5,001,741,440 6.15%
Private Fund GAV* 5,001,741,441 6.15%
Avg Account Size 1,000,348,288 6.15%
SMA’s No
Private Funds 3
Contact Info 415 xxxxxxx
Websites

Client Types

- Pooled investment vehicles

Advisory Activities

- Portfolio management for pooled investment vehicles

Compensation Arrangments

- A percentage of assets under your management
- Performance-based fees

Recent News

Reported AUM

Discretionary
Non-discretionary
5B 4B 3B 3B 2B 1B 673M
2015 2016 2017 2018 2019 2020 2021 2022 2023

Private Funds



Employees

Private Funds Structure

Fund Type Count GAV
Fund TypeHedge Fund Count2 GAV$4,916,469,779
Fund TypeVenture Capital Fund Count1 GAV$85,271,662

Similar advisers

Adviser Hedge Fund Liquidity Fund Private Equity Fund Real Estate Fund Securitized Asset Fund Venture Capital Fund Other Fund Total Private Fund GAV AUM #Funds
Adviser SAGE MOUNTAIN ADVISORS, LLC Hedge Fund25.4m Liquidity Fund- Private Equity Fund- Real Estate Fund- Securitized Asset Fund- Venture Capital Fund6.3m Other Fund- Total Private Fund GAV38.0m AUM2.2b #Funds3
Adviser MIG CAPITAL, LLC Hedge Fund1.2b Liquidity Fund- Private Equity Fund- Real Estate Fund- Securitized Asset Fund- Venture Capital Fund- Other Fund- Total Private Fund GAV1.2b AUM1.2b #Funds2
Adviser GLOBAL FRONTIER INVESTMENTS, LLC Hedge Fund38.5m Liquidity Fund- Private Equity Fund- Real Estate Fund- Securitized Asset Fund- Venture Capital Fund56.2m Other Fund- Total Private Fund GAV150.9m AUM398.2m #Funds3
Adviser LIVIAN & CO. Hedge Fund3.6m Liquidity Fund- Private Equity Fund- Real Estate Fund- Securitized Asset Fund- Venture Capital Fund1.1m Other Fund- Total Private Fund GAV5.7m AUM123.5m #Funds3
Adviser CORAL CAPITAL MANAGEMENT LLC Hedge Fund43.9m Liquidity Fund- Private Equity Fund- Real Estate Fund- Securitized Asset Fund- Venture Capital Fund17.2m Other Fund- Total Private Fund GAV78.2m AUM- #Funds4
Adviser ZILKHA INVESTMENTS, L.P. Hedge Fund65.6m Liquidity Fund- Private Equity Fund- Real Estate Fund- Securitized Asset Fund- Venture Capital Fund2.5m Other Fund- Total Private Fund GAV70.6m AUM- #Funds3
Adviser PANTERA CAPITAL Hedge Fund2.7b Liquidity Fund- Private Equity Fund- Real Estate Fund- Securitized Asset Fund- Venture Capital Fund1.8b Other Fund- Total Private Fund GAV6.4b AUM4.2b #Funds14
Adviser MIO PARTNERS, INC. Hedge Fund20.1b Liquidity Fund- Private Equity Fund- Real Estate Fund- Securitized Asset Fund- Venture Capital Fund30.7m Other Fund- Total Private Fund GAV20.2b AUM47.8b #Funds14
Adviser ARCA INVESTMENT MANAGEMENT, LLC Hedge Fund199.2m Liquidity Fund- Private Equity Fund- Real Estate Fund- Securitized Asset Fund- Venture Capital Fund91.5m Other Fund- Total Private Fund GAV382.2m AUM193.8m #Funds6
Adviser ARS INVESTMENT PARTNERS, LLC Hedge Fund13.8m Liquidity Fund- Private Equity Fund- Real Estate Fund- Securitized Asset Fund- Venture Capital Fund7.1m Other Fund- Total Private Fund GAV27.9m AUM1.6b #Funds4

Top Holdings

Stock Ticker Stock Name $ Position % Position $ Change # Change
Stck Ticker03753U106 Stock NameAPELLIS PHARMACEUTICALS INC $ Position$445,260,823 % Position14.00% $ Change-33.00% # Change2.00%
Stck Ticker803607100 Stock NameSAREPTA THERAPEUTICS INC $ Position$222,356,876 % Position7.00% $ Change-11.00% # Change-27.00%
Stck TickerG72800108 Stock NamePROTHENA CORP PLC $ Position$239,099,539 % Position7.00% $ Change-17.00% # Change0.00%
Stck Ticker032724106 Stock NameANAPTYSBIO INC $ Position$188,476,861 % Position6.00% $ Change11.00% # Change0.00%
Stck Ticker22663K107 Stock NameCRINETICS PHARMACEUTICALS IN $ Position$186,119,246 % Position6.00% $ Change-4.00% # Change0.00%
Stck Ticker04335A105 Stock NameARVINAS INC $ Position$179,059,190 % Position5.00% $ Change-36.00% # Change0.00%
Stck Ticker61775R105 Stock NameMORPHIC HLDG INC $ Position$169,768,936 % Position5.00% $ Change102.00% # Change109.00%
Stck Ticker50127T109 Stock NameKURA ONCOLOGY INC $ Position$119,563,474 % Position4.00% $ Change-3.00% # Change0.00%
Stck Ticker36315X101 Stock NameGALAPAGOS NV $ Position$142,640,321 % Position4.00% $ Change-23.00% # Change0.00%
Stck TickerG50871105 Stock NameJAZZ PHARMACEUTICALS PLC $ Position$108,219,097 % Position3.00% $ Change-11.00% # Change0.00%

Brochure Summary

Overview

EcoR1 Capital, LLC (“EcoR1”) is a limited liability company that has been in business since 2012. EcoR1’s manager, controlling owner and portfolio manager is Oleg Nodelman. As of December 31, 2023, EcoR1 had total discretionary net assets under management of approximately $3.858 billion. EcoR1 only manages assets on a discretionary basis. EcoR1 serves as the general partner of and investment adviser to the EcoR1 Capital Funds (the “Capital Funds”), which invest principally, but not solely, in equity and equity-related securities that are issued by biotechnology companies and traded publicly in U.S. and non-U.S. markets. The Capital Funds also invest in illiquid securities (generally, restricted securities of public and private companies). EcoR1 also serves as the investment adviser to the EcoR1 Venture Opportunity Funds (the “Venture Funds”), which invest principally, but not solely, in restricted equity and equity-related securities issued by privately-held biotechnology companies globally. EcoR1 intends to allocate investment opportunities in such restricted securities between the Capital Funds and the Venture Funds as described in each fund’s offering materials. In the future, EcoR1 may, but is not required to, offer one or more
investors in its funds or clients (or any other persons) the right to participate in investments in which the Capital Funds or the Venture Funds participate if (a) EcoR1 believes that such participation would benefit those funds or the portfolio company or (b) EcoR1 determines that those funds have been allocated the full amount of such investment in the portfolio company in light of their risk-return profiles, available capital and other considerations EcoR1 determines to be relevant. Any such fund that may be established in the future is called an “SPV” and collectively, the “SPVs.” The Capital Funds, the Venture Funds and the SPVs are collectively referred to herein as “clients” or “funds.” EcoR1 selects all fund investments and strategies. While the offering documents for each fund describes the specific investment strategy that EcoR1 intends to follow for that fund, EcoR1 is generally authorized to enter into any type of investment transaction that it deems appropriate under the terms of the applicable fund’s or client account’s governing documents. The investors in the funds that EcoR1 manages have no opportunity to select or evaluate any fund investments or strategies. EcoR1 does not participate in wrap fee programs.